SOUTH
SAN FRANCISCO, Calif., March 10,
2025 /PRNewswire/ -- Rigel Pharmaceuticals,
Inc. (Nasdaq: RIGL) today announced that it has
appointed Mark W. Frohlich, M.D. to its Board of Directors.
Dr. Frohlich is a medical oncologist and brings more than 25 years
of experience developing cellular immunotherapies to treat cancer,
including deep expertise in clinical drug development and
translational research, and portfolio strategy.
"We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His
experience in clinical development, translational research and
portfolio strategy will be a valuable addition to Rigel as we
advance our hematology and oncology development pipeline and grow
our portfolio."
Dr. Frohlich currently serves as chief executive officer of
Indapta Therapeutics, a privately-held biotechnology company
focused on developing and bringing to market allogenic natural
killer cell therapies to treat the still unmet medical needs of
patients with cancer as well as autoimmune diseases. Prior to
joining Indapta, Dr. Frohlich served as a consultant and strategic
advisor for several immuno-oncology biotechnology companies. Before
that, he led portfolio strategy at Juno Therapeutics, which
developed the FDA-approved CAR T-cell therapy Breyanzi®
for large B-cell lymphoma, until the company was sold to Celgene,
now part of Bristol Myers Squibb. Prior to joining Juno, he held
various roles at Dendreon Corporation, a pioneer in the development
of cellular immunotherapy, with his most recent role being chief
medical officer and executive vice president of Research &
Development. At Dendreon, he led the clinical team responsible for
the development and U.S. and European regulatory approval of
PROVENGE®, one of the first commercially available
cancer immunotherapies.
Prior to joining Dendreon, Dr. Frolich was an assistant adjunct
professor of hematology/oncology at the University of California, San Francisco (UCSF),
where he specialized in urologic oncology and conducted laboratory,
translational and clinical research. Dr. Frohlich earned a B.S. in
Electrical Engineering and Economics from Yale College and an M.D.
from Harvard Medical School. At UCSF,
he served as chief resident in medicine and completed a fellowship
in hematology/oncology and a Howard
Hughes postdoctoral fellowship.
"I am excited to join Rigel as it continues to advance its
development pipeline," said Dr. Frohlich. "I believe the IRAK1/4
and IDH1 inhibitor programs have a significant potential to benefit
patients with lower-risk myelodysplastic syndrome and glioma,
respectively. I look forward to collaborating with the team as we
further study these product candidates with the goal of bringing
them to patients that need new treatment options."
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology
company dedicated to discovering, developing and providing novel
therapies that significantly improve the lives of patients with
hematologic disorders and cancer. Founded in 1996, Rigel is based
in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products,
visit www.rigel.com.
Contact for Investors &
Media:
Investors:
Rigel Pharmaceuticals,
Inc.
650.624.1232
ir@rigel.com
Media:
David
Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-appoints-mark-w-frohlich-md-to-board-of-directors-302396483.html
SOURCE Rigel Pharmaceuticals, Inc.
